



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/771,418	02/05/2004	Henrik S. Olsen	PF363C2	4060

22195 7590 12/14/2005
HUMAN GENOME SCIENCES INC
INTELLECTUAL PROPERTY DEPT.
14200 SHADY GROVE ROAD
ROCKVILLE, MD 20850

EXAMINER

BELYAVSKIY, MICHAIL A

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED: 12/14/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/771,418	Applicant(s) OLSEN ET AL.	
	Examiner Michail A. Belyavskyi	Art Unit 1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 20 September 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 23-82 is/are pending in the application.
- 4a) Of the above claim(s) 37-39, 54- 56, 67-69, 80-82 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 23-36, 40-53, 57-66 and 70-79 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

RESPONSE TO APPLICANT'S AMENDMENT

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 09/20/05 has been entered.

Claims 23-82 are pending.

2. Claims 37-39, 54-56, 67-69, 80-82 stand withdrawn from further consideration by the Examiner, 37 C.F.R. § 1.142(b) as being drawn to nonelected inventions.

3. Claims 23-36, 40-53, 57-66 and 70-79 reads on an isolated antibody that specifically binds to an FcR-V polypeptide of claims 23, 40, 57 and 70 are under consideration in the instant application.

In view of the amendment, filed 02/15/05 the following rejections remain:

4. 35 U.S.C. § 101 reads as follows:

"Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title".

5. Claims 23-36 and 40-53, 57-66, 70-79 stand rejected under 35 U.S.C. 101 as the claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility for the same reasons set forth in the previous Office Action, mailed on 04/21/05

Applicant's arguments, filed 09/20/05 have been fully considered, but have not been found convincing.

Art Unit: 1644

Applicant asserts that : (i) based in part on homology to the Fc- γ 2 receptor, the Specification disclosed that the FcR-V polypeptides are important in the regulation of the immune and hematopoietic system and are **thought to function** as an important trigger of complex immune responses including phagocytosis, antibody-dependant cellular cytotoxicity and release of inflammatory mediators; (ii) the specification teaches that the FcR-V polypeptides are useful for the diagnosis or treatment of specific immune system-related disorders, as recited on page 60, paragraph 0135; (iii) the specification on page 13, paragraph 0024 disclosed that FcR-V polypeptide are expressed in specific cells (iv) sequence alignment showing that LIR -7 polypeptide and FcR-V polypeptide were identical at amino acid position -16 to 449. The sequence of LIR-7 has been disclosed by Tedla et al, not by Borges et al. Post-filing reference Tedla et al., corroborate the specific and substantial utility for LIR -7 polypeptide.

Contrary to Applicant's assertion as has been discussed in the previous Office Action, the specification disclosed a purified polypeptide of SEQ ID NO: 10 encoding a novel protein FcR-V (see page 4, paragraph 0012 and page 16, paragraph 0032 in particular). The specification fails to provide sufficient objective evidence of any activity for encoded protein. Applicant only states that said protein shows sequence homology with many FcRs and KIRs , for example about 55.5 % similarity with bovine Fc- γ 2 receptor. The Specification further disclosed that FcR-V may be involved in regulation of the immune and hematopoietic systems . (see overlapping pages 4-5, paragraph 0012 and page 18, paragraph 0037 in particular). Based upon homology to related molecules the specification disclosed that said protein may play a role in one or more aspects of regulating the immune system and tumor cell biology (page 58 , paragraph 0131 in particular). It is also said that novel FcR-V protein is broadly expressed in various cells and tissues (page 13, paragraph 0024 in particular). The specification also disclosed that antibody that specifically recognized polypeptide of SEQ ID:10 are useful to provide immunological probe for differential identification of the tissue or cell type or for treating various diseases (see page 14, paragraph 0025 and page 68, paragraph 0162 in particular).

There is no information pertaining to the significance of the percentage homology, e.g. whether there were any conserved motifs that would led the artisan to accept the protein's function. Moreover, neither the specification nor the prior art disclose any information regarding the evolutionary significance of this homology or relative conservation of structure and function across species. For example, there is no evidence of record showing why homology to a bovine Fc- γ 2 receptor would provide a better basis for assigning protein function than homology to a primate species. It is noted that homology search analysis shows that polypeptide of SEQ ID NO:10 shows 63 % amino acid sequence homology to human gp49 polypeptide or 63 % homology to LIR polypeptide or 50 % homology to murine regulation protein p91 (see attached sequence search analysis). Identifying a protein as having a limited homology to said proteins does not indicate what function it might have. No well-established utility for a FcR-V protein encoded by SEQ ID NO:10 is indicated. After further research, specific and substantial utility might be found for claimed polypeptide of SEQ ID NO:10 and antibody, that specifically recognized said polypeptide. This further characterization, however is part of the act of invention and until it has been undertaken, Applicant's claimed invention is incomplete. A well-

Art Unit: 1644

established utility is a specific, substantial, and utility that is well known, immediately apparent, or implied by the specification's disclosure of the properties of a material.

With regards to the issue that "the specification teaches that the FcR-V polypeptides are useful for the diagnosis or treatment of specific immune system-related disorders, as recited on page 60, paragraph 0135".

The passage pointed by Applicant only generally stated that FcR-V polypeptides may be useful for diagnosis or treatment of various immune system-related disorders involving abnormally high or low expression of FcR-V activities. In other words, at the time the invention was made Applicant does not know and does not disclose any specific diseases or conditions known to be associated with the FcR-V polypeptide, encoded by SEQ ID NO:10 or any conditions associated with altered levels (increase or decrease) of said polypeptide. Since any protein or antibody to said protein may potentially be used as a treatment agent, this utility would not be considered to be specific. Since no particular disease or condition is disclosed, the artisan would have been required to perform additional experimentation to identify and/or reasonably confirm the asserted use of FcR-V polypeptide or antibody to said polypeptide as a treatment agent and therefore, this utility would not be considered to be substantial. Therefore, identification of antibody that binds specifically to FcR-V polypeptide would not be sufficient to identify or confirm a "real world" context of use; clearly further research would be required to identify a disease in which the encoded protein is involved that can be treated using said antibody.

With regards to Applicant's comments that "the specification on page 13, paragraph 0024 disclosed that FcR-V polypeptide are expressed in specific cells"

Contrary to Applicant's assertion the passage pointed by Applicant generally stated that FcR-V polypeptide is expressed "not only in activated monocytes, primary dendritic cells, macrophages **but also in several additional cell and tissue**". In other words, at the time the invention was made Applicant does not know and does not disclose any cell-specific expression of FcR-V polypeptide. Moreover, tissue-specific or cell-specific expression does not rely on specific properties or functions of the encoded protein. Each polypeptide encoded by specific amino acid sequence is expressed within a multicellular organism in some cell type and this expression is regulated in either a temporal or spatial manner. That is, each expressed sequence is expressed in some cell type at some point in a host's lifetime. Some polypeptides are expressed embryonically, others are expressed only in particular cells, while still others are expressed in a wide variety of cells. In addition, some polypeptides which are expressed in particular cells are only expressed in response to certain metabolic or environmental stimuli. Therefore, mere expression does not appear to provide evidence of a specific and substantial utility based on the knowledge of the skilled artisan and the data presented in the instant specification.

The instant claims are drawn to an antibody that specifically recognized FcR-V polypeptide of as yet undetermined function or biological significance. There is no evidence of record or any line of reasoning that would support the conclusion that FcR-V polypeptide of the instant application or antibody that specifically recognized said polypeptide was, as of the filing date,

Art Unit: 1644

useful for therapeutic and diagnostic application, as stated on page 58, paragraph 0131 or for treatment, as stated on page 68, paragraph 0162. Until some actual and specific significance can be attributed to the polypeptide identified in the specification as FcR-V polypeptide, one of the ordinary skill in the art would be required to perform additional experimentation in order to determine how to use the claimed invention. Thus, there was no immediately apparent or "real world" utility as of the filing date.

Thus, the disclosed utilities do not appear to be either specific or substantial because the specification fails to disclose a specific and substantial utility for a polypeptide of SEQ ID NO:10. Therefore it appears that a polypeptide of SEQ ID NO:10 and antibody that binds specifically to said polypeptide constitute research reagents for further experimentation to discover a "real world" utility for the claimed invention.

With regards to Applicant's statement that "sequence of LIR-7 has been disclosed by Tedla et al. not by Borges et al" and "sequence alignment showing that LIR-7 polypeptide and FcR-V polypeptide were identical at amino acid position -16 to 449 and that post-filing reference Tedla et al., corroborate the specific and substantial utility described in the specification".

Applicant's attention is respectively drawn to Fig. 1 of Borges et al., wherein the sequence of LIR-7 is disclosed. Moreover, the sequence alignment of claimed SEQ ID NO:10 shows 100% identity over amino acid sequence at position 1-349 with the referenced in Borges et al., sequence (see attached sequence alignment). It is also noted that the total size of the claimed SEQ ID NO: 10 is 514 amino acid, thus it is not 100% identical to LIR-7.

Moreover, contrary to Applicant's assertion, Tedla et al., only teach that human eosinophils and neutrophils have a restricted pattern of cell-surface LIR expression with LIR3 and LIR7 being expressed in almost all donors. Tedla et al., further teach that LIR7 may have a possible function in tempering Th2 cell dependent inflammatory response however, there is no recitation of FcR-V polypeptide or possible function of said polypeptide in inflammatory response. In addition, as has been discussed supra, the current state of the art is that making functional assignments merely on the basis of some degree of similarity between sequences is unreliable.

Thus, for the above mentioned reasons there does not appear to be either a specific and substantial asserted utility, or a well-established utility for the claimed: an isolated antibody that binds specifically to an Fc RV-polypeptide of Claims 23, 40, 57 and 70.

In addition, since an FcR-V-polypeptide of Claims 23, 40, 57 and 70 and antibody to said polypeptide appears to constitute a research reagent, an isolated cell and hybridoma that produces said antibody also do not appear to have a specific and substantial utility, or a well established utility.

Applicant is directed to the Utility Examination Guidelines, Federal Register, Vol. 66, No. 4, pages 1092-1099, Friday January 5, 2001.

Art Unit: 1644

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 23-36, 40-53, 57-66 and 70-79 also stand rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial, asserted utility or a well established utility for the reasons set forth in the rejection under 35 USC101 above, one skilled in the art clearly would not know how to use the claimed invention for the same reasons set forth in the previous Office Action, 04/21/05

Applicant's arguments, filed 09/20/05 have been fully considered, but have not been found convincing.

Applicant asserts that in view of the present application disclosure of a specific and substantial asserted utility for FcR-V proteins, one skilled in the art would know how to use the claimed invention.

Contrary to Applicant's assertion, as has been discussed supra, it is the Examiner position that claimed FcR-V protein and antibody that specifically binds to said protein do not have a specific and substantial asserted utility. Thus one skilled in the art clearly would not know how to use the claimed invention.

8. No claim is allowed.


Art Unit: 1644

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is 571/ 272-0840. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571/ 272-0841.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michail Belyavskyi, Ph.D.
Patent Examiner
Technology Center 1600
December 12, 2005

A handwritten signature in black ink, appearing to read 'Michail Belyavskyi', with a long horizontal line extending to the right.